Cliff Asness's CTMX Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 42,014 shares of CytomX Therapeutics, Inc. (CTMX) worth $157,553, representing 0.00% of the portfolio. First purchased in 2017-Q2, this long-term strategic position has been held for 22 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in CTMX, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2022, adding 391,860 shares. Largest reduction occurred in Q3 2022, reducing 391,860 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's CytomX Therapeutics (CTMX) Holding Value Over Time
Track share changes against reported price movement
Quarterly CytomX Therapeutics (CTMX) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +42,014 | New Buy | 42,014 | $3.75 |
| Q3 2022 | -391,860 | Sold Out | 0 | $0.00 |
| Q2 2022 | +391,860 | New Buy | 391,860 | $1.83 |
| Q4 2021 | -17,486 | Sold Out | 0 | $0.00 |
| Q3 2021 | -116,799 | Reduce 86.98% | 17,486 | $5.09 |
| Q2 2021 | +33,277 | Add 32.94% | 134,285 | $6.33 |
| Q1 2021 | -22,921 | Reduce 18.50% | 101,008 | $7.73 |
| Q4 2020 | +1,937 | Add 1.59% | 123,929 | $6.55 |
| Q3 2020 | -68,333 | Reduce 35.90% | 121,992 | $6.65 |
| Q2 2020 | +49,986 | Add 35.62% | 190,325 | $8.33 |
| Q1 2020 | +8,781 | Add 6.67% | 140,339 | $7.67 |
| Q4 2019 | +76,900 | Add 140.69% | 131,558 | $8.31 |
| Q3 2019 | +16,201 | Add 42.13% | 54,658 | $7.37 |
| Q2 2019 | +16,356 | Add 74.01% | 38,457 | $11.21 |
| Q1 2019 | +3,482 | Add 18.70% | 22,101 | $10.77 |
| Q4 2018 | -13,871 | Reduce 42.69% | 18,619 | $15.09 |
| Q3 2018 | -8,723 | Reduce 21.17% | 32,490 | $18.50 |
| Q2 2018 | -4,499 | Reduce 9.84% | 41,213 | $22.86 |
| Q1 2018 | -49,675 | Reduce 52.08% | 45,712 | $28.46 |
| Q4 2017 | +42,751 | Add 81.22% | 95,387 | $21.11 |
| Q3 2017 | +38,925 | Add 283.90% | 52,636 | $18.16 |
| Q2 2017 | +13,711 | New Buy | 13,711 | $15.53 |
Cliff Asness's CytomX Therapeutics Investment FAQs
Cliff Asness first purchased CytomX Therapeutics, Inc. (CTMX) in Q2 2017, acquiring 13,711 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held CytomX Therapeutics, Inc. (CTMX) for 22 quarters since Q2 2017.
Cliff Asness's largest addition to CytomX Therapeutics, Inc. (CTMX) was in Q2 2022, adding 391,860 shares worth $717,000.
According to the latest 13F filing for Q2 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 42,014 shares of CytomX Therapeutics, Inc. (CTMX), valued at approximately $157,553.
As of the Q2 2026 filing, CytomX Therapeutics, Inc. (CTMX) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in CytomX Therapeutics, Inc. (CTMX) was 391,860 shares, as reported at the end of Q2 2022.